Colin Campbell

Colin Campbell serves as the Sr Director and Head of Manufacturing Sciences and Technology at Actinium Pharmaceuticals, Inc., overseeing process development, scale-up, and validation for radiopharmaceuticals, along with regulatory submissions such as IND, BLA, and MAA since January 2023. Previously, at Bristol-Myers Squibb, Colin led CAR-T manufacturing operations for Breyanzi®, managing a team of over 350 associates and exceeding operational goals from February 2020 to January 2023. A background in downstream process development was established at Immunomedics, while earlier roles at Elusys Therapeutics, Roche Molecular Systems, ICN Pharmaceuticals, and the American Health Foundation provided extensive experience in process development, scale-up, and GMP manufacturing. Colin holds a Bachelor of Science degree in Biochemistry from Rutgers University, Cook College.